Please assess the completion status of the following clinical trial:

Trial Title: Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult female 18 years to 45 years of age who experienced GDM within 52 weeks of index pregnancy~* Actual BMI \>25 kg/ m2~* Written consent for participation in the study~* Patient completed lactation~* Dysglycemia (impaired fasting glucose \[IFG}, impaired glucose tolerance \[IGT} or IFG/IGT) and/or ß-cell dysfunction postpartum requiring pharmacological intervention (except type 1 or 2 diabetes)~Exclusion Criteria:~Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2~* History of pancreatitis~* Significant cardiovascular, cerebrovascular, renal, or hepatobiliary diseases in the past (viral hepatitis, toxic hepatic damage, jaundice of unknown etiology)~* Serum liver enzymes (AST and/or ALT levels) exceeding more than twice normal laboratory values~* Uncontrolled hypertension (systolic blood pressure\>150 mm Hg and/or diastolic blood pressure \>90 mm Hg)~* Fasting serum triglycerides ≥800 mg/dl at screening. Lipid-lowering medications must have been maintained at the same dose for 3 months prior to enrollment~* Hematological profiles considered to be clinically significant~* Cholestasis during the past pregnancy~* Presence of contradictions for GLP-1 receptor agonist or metformin administration such as allergy or hypersensitivity~* Current use of metformin, thiazolidinediones, dipeptidyl peptidase-4 inhibitors or GLP-1 receptor agonist medications.~* Use of drugs known to exacerbate glucose tolerance.~* Use of prescription or over-the-counter weight-loss drugs~* Diabetes postpartum or history of diabetes or prior use of medications to treat diabetes except gestational diabetes~* Creatinine clearance less than 60 ml/min~* History or currently undergoing chemotherapy or radiotherapy for cancer~* Pregnancy planned during the coming two years~* Currently breastfeeding~* Exclusion criteria include any condition, which in the opinion of the investigator would place the subject at increased risk or otherwise make the subject unsuitable for participation in the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Metformin XR plus liraglutide (Type: EXPERIMENTAL): Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated
- Metformin XR plus placebo (Type: ACTIVE_COMPARATOR): Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete